1 |
Kim, J. K., Fillmore, J. J., Gavrilova, O., Chao, L., Higashimori, T., Choi, H., Kim, H. J., Yu, C., Chen, Y., Qu, X., Haluzik, M., Reitman, M. L. and Shulman, G. I. (2003) Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52, 1311-1318.
DOI
ScienceOn
|
2 |
Nan, Y. M., Fu, N., Wu, W. J., Liang, B. L., Wang, R. Q., Zhao, S. X., Zhao, J. M. and Yu, J. (2009) Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand. J. Gastroenterol. 44, 358-365.
|
3 |
Lutchman, G., Modi, A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T. J., Premkumar, A. and Hoofnagle, J. H. (2007) The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46, 424-429.
DOI
ScienceOn
|
4 |
Musso, G., Cassader, M., Rosina, F. and Gambino, R. (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885-904.
DOI
ScienceOn
|
5 |
Kallwitz, E. R., McLachlan, A. and Cotler, S. J. (2008) Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 14, 22-28.
DOI
|
6 |
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J. and Reitman, M. L. (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268-34276.
DOI
ScienceOn
|
7 |
Lee, C. H. and Evans, R. M. (2002) Peroxisome proliferator-activated receptor- in macrophage lipid homeostasis. Trends Endocrinol. Metab. 13, 331-335.
DOI
ScienceOn
|
8 |
Hevener, A. L., Olefsky, J. M., Reichart, D., Nguyen, M. T., Bandyopadyhay, G., Leung, H. Y., Watt, M. J., Benner, C., Febbraio, M. A., Nguyen, A. K., Folian, B., Subramaniam, S., Gonzalez, F. J., Glass, C. K. and Ricote, M. (2007) Macrophage is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117, 1658-1669.
DOI
ScienceOn
|
9 |
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Red Eagle, A., Vats, D., Brombacher, F., Ferrante, A. W. and Chawla, A. (2007) Macrophage-specific controls alternative activation and improves insulin resistance. Nature 447, 1116-1120.
DOI
ScienceOn
|
10 |
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S. and Lazar, M. A. (2001) The hormone resistin links obesity to diabetes. Nature 409, 307-312.
DOI
ScienceOn
|
11 |
Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, R., Kimura, S. and Kadowaki T. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and agonist improve insulin resistance. J. Biol. Chem. 276, 41245-41254.
DOI
ScienceOn
|
12 |
Guan, H. P., Li, Y., Jensen, M. V., Newgard, C. B., Steppan, C. M. and Lazar, M. A. (2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8, 1122-1128.
DOI
ScienceOn
|
13 |
Peraldi P., Xu, M. and Spiegelman, B.M. (1997) Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest. 100, 1863-1869.
DOI
ScienceOn
|
14 |
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M. and Evans, R. M. (2013) signaling and metabolism: the good, the bad and the future. Nat. Med. 19, 557-566.
|
15 |
Rajala, M. W., Obici, S., Scherer, P. E. and Rossetti, L. (2003) Adipose-derived resistin and gut-derived resistin-like molecule-gselectively impair insulin action on glucose production. J. Clin. Invest. 111, 225-300.
DOI
ScienceOn
|
16 |
Combs T. P., Berg A. H., Obici S., Scherer P. E. and Rossetti, L. (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108, 1875-1881.
DOI
ScienceOn
|
17 |
Berg, A. H., Combs, T. P., Du, X., Brownlee, M. and Scherer, P. E. (2001) The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953.
DOI
ScienceOn
|
18 |
Miles, P. D., Barak, Y., He, W., Evans, R. M. and Olefsky, J. M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105, 287-292.
DOI
ScienceOn
|
19 |
Tang, X., Guilherme, A., Chakladar, A., Powelka, A. M., Konda, S., Virbasius, J. V., Nicoloro, S. M., Straubhaar, J. and Czech, M. P. (2006) An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPAR gamma, adipogenesis, and insulin-responsive hexose transport. Proc. Natl. Acad. Sci. U.S.A. 103, 2087-2092.
DOI
ScienceOn
|
20 |
Gregoire, F. M., Zhang, F., Clarke, H. J., Gustafson, T. A., Sears, D. D., Favelyukis,S., Lenhard, J., Rentzeperis, D., Clemens, L. E., Mu, Y. and Lavan, B. E. (2009). MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol. Endocrinol. 23, 975-988.
DOI
ScienceOn
|
21 |
Zhang, B., Berger, J., Zhou, G., Elbrecht, A., Biswas, S., White-Carrington, S., Szalkowski, D. and Moller, D. E. (1996) Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 271, 31771-31774.
DOI
ScienceOn
|
22 |
Berger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., Doebber, T. W., Biswas, C., Parikh, M., Sharma, N., Tanen, M. R., Thompson, G. M., Ventre, J., Adams, A. D., Mosley, R., Surwit, R. S. and Moller, D. E. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 17, 662-676.
DOI
ScienceOn
|
23 |
Camp, H. S. and Tafuri, S. R. (1997) Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem. 272, 10811-10816.
DOI
ScienceOn
|
24 |
Reginato, M. J., Krakow, S. L., Bailey, S. T. and Lazar, M. A. (1998) Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 273, 1855-1858.
DOI
ScienceOn
|
25 |
Adams, M., Reginato, M. J., Shao, D., Lazar, M. A. and Chatterjee, V. K. (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site. J. Biol. Chem. 272, 5128-5132.
DOI
ScienceOn
|
26 |
Shao, D., Rangwala, S. M., Bailey, S. T., Krakow, S. L., Reginato, M. J. and Lazar, M. A. (1998) Interdomain communication regulating ligand binding by PPAR-gamma. Nature 396, 377-380.
DOI
ScienceOn
|
27 |
Iankova, I., Petersen, R. K., Annicotte, J. S., Chavey, C., Hansen, J. B., Kratchmarova, I., Sarruf, D., Benkirane, M., Kristiansen, K. and Fajas, L. (2006) Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol. Endocrinol. 20, 1494-1505.
DOI
ScienceOn
|
28 |
Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Bostrom, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Bluher, M., Griffin, P. R. and Spiegelman, B. M. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456.
DOI
ScienceOn
|
29 |
Rangwala, S. M., Rhoades, B., Shapiro, J. S., Rich, A. S., Kim, J. K., Shulman, G. I., Kaestner, K. H. and Lazar, M. A. (2003) Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell 5, 657-663.
DOI
ScienceOn
|
30 |
Compe, E., Drane, P., Laurent, C., Diderich, K., Braun, C., Hoeijmakers, J. H. and Egly, J. M. (2005) Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Mol. Cell. Biol. 25, 6065-6076.
DOI
ScienceOn
|
31 |
Dhavan, R. and Tsai, L. H. (2001) A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759.
DOI
ScienceOn
|
32 |
Li P, Fan W, Xu, J., Lu, M., Yamamoto, H., Auwerx, J., Sears, D. D., Talukdar, S., Oh, D., Chen, A., Bandyopadhyay, G., Scadeng, M., Ofrecio, J. M., Nalbandian, S. and Olefsky, J. M. (2011) Adipocyte NCoR knockout decreases phosphorylation and enhances activity and insulin sensitivity. Cell 147, 815-826.
DOI
ScienceOn
|
33 |
Geiss-Friedlander, R. and Melchior, F. (2007) Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947-956.
DOI
ScienceOn
|
34 |
Floyd, Z. E. and Stephens, J. M. (2002) Interferon-gammamediated activation and ubiquitin-proteasomedependent degradation of PPAR gamma in adipocytes. J. Biol. Chem. 277, 4062-4068.
DOI
ScienceOn
|
35 |
Werman, A., Hollenberg, A., Solanes, G., Bjorbaek, C., Vidal-Puig, A. J. and Flier, J. S. (1997) Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J. Biol. Chem. 272, 20230-20235.
DOI
ScienceOn
|
36 |
Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M., Palvimo, J. J., Nakai, A. and Sistonen, L. (2006) PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. U.S.A. 103, 45-50.
DOI
ScienceOn
|
37 |
Yamashita, D., Yamaguchi, T., Shimizu, M., Nakata, N., Hirose, F. and Osumi, T. (2004) The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 9, 1017-1029.
DOI
ScienceOn
|
38 |
Dutchak, P. A., Katafuchi, T., Bookout, A. L., Choi, J. H., Yu, R. T., Mangelsdorf, D. J. and Kliewer, S. A. (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556-567.
DOI
ScienceOn
|
39 |
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G. and Glass, C. K. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759-763.
DOI
ScienceOn
|
40 |
Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E. and Spiegelman, B. M. (2000) Degradation of the peroxisome proliferatoractivated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 275, 18527-18533.
DOI
ScienceOn
|
41 |
Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M., Zhao, Y., Gu, W., Farmer, S. R. and Accili, D. (2012) Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of . Cell 150, 620-632.
DOI
ScienceOn
|
42 |
Kilroy, G. E., Zhang, X. and Floyd, Z. E. (2009) PPAR-gamma AF-2 domain functions as a component of a ubiquitin- dependent degradation signal. Obesity (Silver Spring) 17, 665-673.
DOI
ScienceOn
|
43 |
Ji, S., Park, S. Y., Roth, J., Kim, H. S. and Cho, J.W. (2012) O-GlcNAc modification of reduces its transcriptional activity. Biochem. Biophys. Res. Commun. 417, 1158-1163.
DOI
ScienceOn
|
44 |
Li, A., Xue, Y., Jin, C., Wang, M. and Yao, X. (2006) Prediction of Nepsilon-acetylation on internal lysines implemented in Bayesian Discriminant Method. Biochem. Biophys. Res. Commun. 350, 818-824.
DOI
ScienceOn
|
45 |
Acton, J. J. 3rd., Black, R. M., Jones, A. B., Moller, D. E., Colwell, L., Doebber, T. W., Macnaul, K. L., Berger, J. and Wood, H. B. (2005) Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 15, 357-362.
DOI
ScienceOn
|
46 |
Choi, J. H., Banks, A. S., Kamenecka, T. M., Busby, S. A., Chalmers, M. J., Kumar, N., Kuruvilla, D. S., Shin, Y., He, Y., Bruning, J. B., Marciano, D. P., Cameron, M. D., Laznik, D., Jurczak, M. J., Schurer, S. C., Vidovic, D., Shulman, G. I., Spiegelman, B. M. and Griffin, P. R. (2011) Antidiabetic actions of a non-agonist ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-481.
DOI
ScienceOn
|
47 |
Harms, M. and Seale P. (2013) Brown and beige fat: development, function and therapeutic potential. Nat. Med. 19, 1252-1263.
DOI
ScienceOn
|
48 |
Ohno, H., Shinoda, K., Spiegelman, B. M. and Kajimura, S. (2012) agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 15, 395-404.
DOI
ScienceOn
|
49 |
Chawla, A., Repa, J. J., Evans, R. M. and Mangelsdorf, D. J. (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 5548, 1688-1670.
|
50 |
Reddy, J. K. and Hashimoto, T. (2001) Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21, 193-230.
DOI
ScienceOn
|
51 |
Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
DOI
ScienceOn
|
52 |
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G. and Wahli, W. (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887.
DOI
ScienceOn
|
53 |
Evan, R. M., Barish, G. D. and Wang, Y. X. (2004) PPARs and the complex journey to obesity. Nat. Med. 10, 355-361.
DOI
ScienceOn
|
54 |
Lehmann, J. M., Moore, L. B., Smith-oliver, T., A., Wilkison, W., O., Willson, T., M. and Kliewer, S., A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956.
DOI
ScienceOn
|
55 |
Peters, J. M., Lee, S. S, Li W., Ward, J. M., Gavrilova, O., Everett, C., Reitman, M. L., Hudson, L. D. and Gonzalez, F. J. (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20, 5119-5128.
DOI
ScienceOn
|
56 |
Oliver, W. R. Jr., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., Xu, H. E., Sternbach, D. D., Kliewer, S. A., Hansen, B. C. and Willson, T. M. (2001) A selective peroxisome proliferator-activated receptors-delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98, 5306-5311.
DOI
ScienceOn
|
57 |
Riserus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., Strum, J. C., Basu, S., Cheeseman, J., Fielding, B. A., Humphreys, S. M., Danoff, T., Moore, N. R., Murgatroyd, P, O'Rahilly, S., Sutton, P., Willson, T., Hassall, D., Frayn, K. N. and Karpe, F. (2008) Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57, 332-339.
DOI
ScienceOn
|
58 |
Berger, J., Patel, H. V., Woods, J., Hayes, N. S., Parent, S. A., Clemas, J., Leibowitz, M. D., Elbrecht, A., Rachubinski, R. A., Capone, J. P. and Moller, D. E. (2000) A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol. Cell. Endocrinol. 162, 57-67.
DOI
ScienceOn
|
59 |
Tontonoz, P., Hu, E. and Spiegelman, B. M. (1994) Stimulation of adipogenesis in fibroblasts by 2, a lipid-activated transcription factor. Cell 79, 1147-1156.
DOI
ScienceOn
|
60 |
Tontonoz, P. and Spiegelman, B. M. (2008) Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289-312.
DOI
ScienceOn
|
61 |
Barroso, I., Gurnell, M., Crowle,y V. E., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D., Lewis, H., Schafer, A. J., Chatterjee, V. K. and O'Rahilly, S. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883.
|
62 |
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A. and Evans, R. M. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595.
DOI
ScienceOn
|
63 |
Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S., Spiegelman, B. M. and Mortensen, R. M. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611-617.
DOI
ScienceOn
|
64 |
Gray, S. L., Nora, E. D., Grosse, J., Manieri, M., Stoeger, T., Medina-Gomez, G., Burling, K., Wattler, S., Russ, A., Yeo, G. S., Chatterjee, V. K., O'Rahilly, S., Voshol, P. J., Cinti, S. and Vidal-Puig, A. (2006) Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 55, 2669-2677.
DOI
ScienceOn
|
65 |
Tamori, Y., Masugi, J., Nishino, N. and Kasuga, M. (2002) Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51, 2045-2055.
DOI
ScienceOn
|
66 |
Hevener, A. L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Wilkes, J., Evans, R. M. and Olefsky, J. (2003) Muscle-specific PPARg deletion causes insulin resistance. Nat. Med. 9, 1491-1497.
DOI
ScienceOn
|
67 |
Matsusue, K., Haluzik, M., Lambert, G., Yim, S. H., Gavrilova, O., Ward, J. M., Brewer, B., Jr., Reitman, M. L. and Gonzalez, F. J. (2003) Liverspecific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111, 737-747.
DOI
ScienceOn
|
68 |
Rangwala, S. M., Rhoades, B., Shapiro, J. S., Rich, A. S., Kim, J. K., Shulman, G. I., Kaestner, K. H. and Lazar, M. A. (2003) Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell 5, 657-663.
DOI
ScienceOn
|
69 |
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M. and Evans, R. M. (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100, 15712-15717.
DOI
ScienceOn
|
70 |
Agarwal, A. K. and Garg, A. (2002) A novel heterozygous mutation in peroxisome proliferatoractivated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87, 408-411.
|
71 |
Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. and Leff, T. (2002) PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51, 3586-3590.
DOI
ScienceOn
|
72 |
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M. and Evans, R. M. (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812.
DOI
ScienceOn
|
73 |
Savage, D. B., Tan, G. D., Acerini, C. L., Jebb, S. A., Agostini, M., Gurnell. M., Williams, R. L., Umpleby, A. M., Thomas, E. L., Bell, J. D., Dixon, A. K., Dunne, F., Boiani, R., Cinti, S., Vidal-Puig, A., Karpe, F., Chatterjee, V. K. and O'Rahilly, S. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52, 910-917.
DOI
ScienceOn
|
74 |
Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688.
|
75 |
Chandra, V., Huang, P., Hmuro, Y., Raghuram, S., wang, Y., Burris, T. P. and Rastinejad, F. (2008) Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456, 350-356.
DOI
|
76 |
Gronemeyer, H., Gustafsson, J. A. and Laudet, V. (2004) Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug. Discov. 3, 950-964.
DOI
ScienceOn
|
77 |
Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G. and Wahli, W. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11, 779-791.
DOI
|
78 |
Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K. and Wahli, W. (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A. 90, 2160-2164.
DOI
|
79 |
Nagy, L., Tontonoz, P., Alvarez, J. G., Chen, H. and Evans, R. M. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93, 229-240.
DOI
ScienceOn
|
80 |
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C. and Lehmann, J. M. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell 83, 813-819.
DOI
ScienceOn
|
81 |
Kung, J. and Henry, R. R. (2012) Thiazolidinedione safety. Expert. Opin. Drug Saf. 11, 565-579.
DOI
ScienceOn
|
82 |
Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. and Olefsky, J. (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193.
DOI
ScienceOn
|
83 |
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M. and Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956.
DOI
ScienceOn
|
84 |
Berger, J., Leibowitz, M. D., Doebber, T. W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C. A., Hayes, N. S., Li, Y., Tanen, M., Ventre, J., Wu, M. S., Berger, G. D., Mosley, R., Marquis, R., Santini C, Sahoo, S. P., Tolman, R. L., Smith, R. G. and Moller, D.E. (1999). Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem. 274, 6718-6725.
DOI
ScienceOn
|
85 |
Ribon, V., Johnson, J. H., Camp, H. S. and Saltiel, A. R. (1998) Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor g activation stimulates expression of the CAP gene. Proc. Natl. Acad. Sci. U.S.A. 95, 14751-14756.
DOI
ScienceOn
|
86 |
Rangwala, S. M. and Lazar, M. A. (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 25, 331-336.
DOI
ScienceOn
|
87 |
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M. and Evans, R. M. (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100, 15712-15717.
DOI
ScienceOn
|
88 |
Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O. and Reitman, M. L. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106, 1221-1228.
DOI
ScienceOn
|
89 |
Matsusue, K., Haluzik, M., Lambert, G., Yim, S. H., Gavrilova, O., Ward, J. M., Brewer, B., Jr., Reitman, M. L. and Gonzalez, F. J. (2003) Liverspecific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111, 737-747.
DOI
ScienceOn
|
90 |
Ye, J. M., Dzamko, N., Cleasby, M. E., Hegarty, B., D., Furler, S. M., Cooney, G. J. and Kraegen, E. W. (2004) Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47, 1306-1313.
DOI
|
91 |
Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S. and Graves, R. A. (1997) Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100, 2900-2908.
DOI
ScienceOn
|
92 |
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., Watanabe, Y., Uchiyama, Y., Sumi, K., Iguchi, H., Ito, S., Doi, T., Hamakubo, T., Naito, M., Auwerx, J., Yanagisawa, M., Kodama, T. and Sakai, J. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100, 15924-15929.
DOI
ScienceOn
|
93 |
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Nagai,, R., Tobe, K., Kimura, S. and Kadowaki T. (1999) PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609.
DOI
ScienceOn
|
94 |
Norris, A. W., Chen, L., Fisher, S. J., Szanto, I., Ristow, M., Jozsi, A. C., Hirshman, M. F., Rosen, E. D., Goodyear, L. J., Gonzalez, F. J., Spiegelman, B. M. and Kahn, C. R. (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112, 608-618.
DOI
ScienceOn
|
95 |
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I. and Petersen, K. F. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797-802.
DOI
ScienceOn
|
96 |
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P. and Kadowaki, T. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946.
DOI
ScienceOn
|
97 |
Hu, E. D., Kim, J. B., Sarraf, P. and Spiegelman, B. M. (1996) Inhibition of adipogenesis through MAP kinase mediated phosphorylation of PPAR gamma. Science 274, 2100-2103.
DOI
ScienceOn
|
98 |
Wang, C., Tian, L., Popov, V. M. and Pestell, R. G. (2011) Acetylation and nuclear receptor action. J. Steroid Biochem. Mol. Biol. 123, 91-100.
DOI
ScienceOn
|
99 |
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B. and Nedergaard, J. (2010) Chronic peroxisome proliferator-activated receptor () activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J. Biol. Chem. 285, 7153-7164.
DOI
ScienceOn
|